A new clinical trial published in the Journal of the American Medical Association found concurrent transcutaneous auricular vagus nerve stimulation (taVNS) therapy to improve both skin symptoms and systemic comorbidities, indicating its potential as an effective treatment for erythematotelangiectatic rosacea (ETR).

The trial from February 2024 to February 2025, involved 72 participants with moderate to severe ETR, identified by a Clinician’s Erythema Assessment (CEA) score of at least 2. The participants were randomly divided into 2 equal groups, where one received daily taVNS therapy, and the other underwent sham stimulation (SS), which mimicked the treatment but provided no actual nerve activation.

The taVNS treatment delivered mild electrical pulses to the auricular branch of the va

See Full Page